Surgery Partners (SGRY) Stock Drops As Idaho Falls Sale Reshapes Debt Story

Surgery Partners stock dropped almost 6% to about US$15 today, even though the latest quarter showed a cleaner story under the hood. Revenue reached roughly US$849 million and adjusted earnings before interest, tax, depreciation and amortization margin held near 14.7%, while management put heavy emphasis on reshaping the portfolio.

The real headline is the planned Idaho Falls divestiture. That deal aims to simplify the business, free up roughly US$795 million of gross proceeds and cut leverage. Short term traders focused on the red quote. Longer term investors will likely focus on the implications of this balance sheet reset in the coming years.

Interested in Surgery Partners’ focus on EBITDA margins and balance sheet repair but concerned about concentration risk and leverage? Check out the list of solid balance sheet and fundamentals stocks (48 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$848.9 million vs. US$826.2 million (up about 2.7% year on year)
• Net Loss, Q2 2026 vs. Q2 2025: loss of US$15.0 million vs. loss of US$2.5 million (loss widened)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.12 per share vs. loss of US$0.02 per share (per share loss increased)
• Adjusted EBITDA Margin, Q2 2026 vs. Q2 2025: about 14.7% vs. prior year margin that management described as comparable (margin held broadly stable)

Prefer clean visuals over another dense page of earnings figures and balance sheet ratios? See Surgery Partners’ full financial picture, including an at a glance view of its balance sheet and debt profile, in the company report for Surgery Partners.

Surgery Partners Bull Case Hinges On Execution Milestones

Bulls argue Surgery Partners can compound value through higher acuity outpatient growth, stronger physician recruitment and cleaner assets. This quarter provides some concrete proof points, but also shows the work still ahead.

On the operations side, same facility revenue grew 5% with case volumes roughly flat and revenue per case up 4.8%. Growth concentrated in orthopedics, spine and vascular, which aligns with the higher acuity outpatient story. The 191 new physicians who started in Q2 and 330 year to date, with a cohort contribution about 16% higher than last year, supports the view that recruiting is gaining traction.

The portfolio simplification narrative also moved from promise to action. The Idaho Falls sale would remove a capital intensive, less aligned hospital asset and generated an agreed US$795m of gross proceeds, which management plans to use largely for debt reduction.

Compare Surgery Partners’ operational story of higher acuity growth, stable adjusted EBITDA margin, and expanding physician cohorts with how the stock traded down about 6% today. See the consensus price target analysis for Surgery Partners to check whether Wall Street’s price targets are keeping pace with that thesis.

Surgery Partners Bear Case Finds Fresh Support

The bearish view on Surgery Partners centers on slow volume growth, pressured margins and high leverage that limits room for error. This quarter does not fully disarm those concerns. Same facility revenue grew 5%, but cases were almost flat and revenue per case did most of the work, which fits the worry that pricing and mix are carrying more of the load than true volume expansion.

On profitability, adjusted EBITDA margin held at 14.7%, yet year to date adjusted EBITDA is lower even as revenue is higher. That points to cost and reimbursement pressure still biting. Interest payments of about US$90 million in Q2 and net leverage around 5.1x keep the balance sheet risk firmly on the table. The Idaho Falls sale trims leverage by only about 0.3 turns. With the stock down about 6% today, the market reaction lines up with several bear case milestones being missed rather than cleared.

With interest costs high, leverage still elevated and losses wider over the past five years, you should verify whether Surgery Partners has the balance sheet strength to finish this turnaround. Analyze the full debt, liquidity and cash runway picture in our financial health analysis of Surgery Partners stock.

Stay Ahead With Surgery Partners Insights

If the mix of higher acuity growth, Idaho Falls divestiture and leverage reduction has Surgery Partners on your radar, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that suits your plan. Once you own it or any other stock, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For a longer term edge, tap into the Community to see how other investors are thinking about similar risks and catalysts. Spot potential turning points early and keep your process a step ahead of the market.

Seeking Alternatives Beyond Surgery Partners?

Fresh ideas move fastest. Some stocks are building breakout momentum while the story is still under the radar for now. Do not get caught dropping in late, get in early.

• Spot resilient cash generators before the crowd by scanning a curated list of solid balance sheet and fundamentals stocks (48 results) while balance sheets and fundamentals still look compelling.
• Ride structural shifts in infrastructure and electrification by reviewing hand picked 37 power grid technology and infrastructure stocks while these stories are still flying under most radars.
• Position ahead of potential robotics momentum by checking curated 37 robotics and automation stocks before fresh automation themes are fully priced in by others.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com